A randomized trial of botulinum toxin A for treatment of drooling.
The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.
Lipp
A
A
Department of Neurology, Medical Faculty of the Charité, Humboldt University, Berlin, Germany.
Trottenberg
T
T
Schink
T
T
Kupsch
A
A
Arnold
G
G
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D016472:Motor Neuron Disease / Q000150:complications; D009465:Neuromuscular Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications; D010306:Parotid Gland / Q000187:drug effects; D011446:Prospective Studies; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A